A Phase 2 Study of INCMGA-0012 in Participants with Metastatic Merkel Cell Carcinoma (PODIUM)

Learn how it’s Safe@Inova

Get the facts on how we’re ensuring safety at our locations, our PPE safety requirements, and more, so you know it’s safe to receive the care you need—as well as safe for us to continue delivering your care. Whether your visit is for routine care, emergency care, or COVID-19 care, you have a nationally recognized leader in safety, ready for you. See temporary restricted visitation policy.

General Information

Age Group

Adults

Status

Recruiting

Protocol Number

NCT03599713

Background Information

The purpose of this study is to test the safety and effectiveness of the study drug INCMGA00012 in participants with Metastatic Merkel Cell Carcinoma.

Offered At

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031

A department of Inova Fairfax Hospital

Eligibility Information

Participants must be 18 years of age or older
Participants must have histologically confirmed MCC with distant metastatic disease as a component of tumor burden and no more than 3 prior systemic treatments, inclusive of systemic adjuvant therapy
Additional eligibility in protocol

Ineligibility Information

Prior programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy
Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders
Additional ineligibility in protocol

For more information go to: https://clinicaltrials.gov/ct2/show/NCT03599713